먹튀없는 바카라사이트 unveils its vision for a ‘Korean Bio Ecosystem’ — built on mutual cooperation and shared growth

[by Ji, Yong Jun] "Celltrion's mission is to help shape the future of the entire Korean biotechnology industry as a whole."

Kwon Ki-sung, Senior Vice President of Celltrion, delivered these remarks during the ‘2025 Pharmaceutical and Bio Investment Fair,’ held at Songdo ConvensiA in Incheon on the morning of December 2. Speaking under the theme ‘The Role of Large Corporations Leading the Global Biotechnology Industry,’ Kwon presented Celltrion's ‘open innovation’ program.

Kwon identified ‘mutually beneficial cooperation’ and ‘shared growth’ as the core guiding principles for Celltrion. "Startups often face significant challenges in securing funding for development and clinical trials, which is why anchor companies must take the lead in establishing a foundation for their growth," he stated.

Since 2022, Celltrion has operated an ‘open innovation team’ with the aim of co-developing early-stage drug candidates in partnership with Korean startups, rather than relying on a later-stage licensing-in strategy.

At the center of Celltrion's open innovation strategy is a commitment to ‘creating an ecosystem.’ Rather than merely securing pipeline assets, the company pursues a targeted approach to fostering startup growth through collaboration with central and local governments, venture capitalists (VCs), and academia. Starting with the Incheon Startup Park initiative, established in collaboration with City of Incheon, Celltrion has expanded its regional collaboration programs to include Seoul, Gangwon Province, and Chungbuk National University. In addition, the company is extending its global reach beyond Japan and the United States, most recently launching an open innovation program in China.

"We are preparing an open innovation program in China through a business agreement with the City of Incheon and have already completed a preliminary survey," Kwon explained. "China plays a pivotal role in global pipeline development. Because early-stage clinical trials can be conducted relatively easily in China, we expect to uncover new opportunities not only for co-development but also for advancing our own internal pipelines," he added.

Kwon also highlighted Celltrion's role in providing investment support. In addition to making its own equity investments, Celltrion manages eight investment funds with a combined value exceeding KRW 1 trillion (approximately USD 681.3 million). "Through the funds currently under management, we act as early-stage investors and conduct direct technology evaluations of promising companies. For early-stage firms, we offer support of up to KRW 600 million for seed or pre-A stage companies through a super-structured venture capital fund," he explained.

This demonstrates that anchor companies are actively investing in and fostering a development environment that addresses the most pressing funding challenges faced by startups. In practice, Celltrion is investing in a range of early-stage companies through collaborations with organizations like Incheon Startup Park and Seoul Biohub. "As seen in our investments in MustBio and Portrai, we will continue to pursue win-win strategies that leverage the broader bio ecosystem," Kwon remarked.

"A truly competitive ‘Korean Bio Ecosystem’ capable of shaping a new order in the global market can only be built when national and regional vision is combined with the entrepreneurial drive of startups, the execution capabilities of the industry, and the research strengths of academia. Celltrion will uphold its responsibility and mission as an anchor company at the center of this effort," Kwon emphasized.